Eli Lilly to Offer Breakthrough Migraine Drug for Free
*By Michael Teich*
[Twelve percent](https://migraineresearchfoundation.org/about-migraine/migraine-facts/) of the U.S. population may suffer from chronic migraines, but many Americans don't appreciate the impact, said president of Lilly Bio-Medicines Christi Shaw.
"These patients need to be treated seriously. This is a neurological disorder," Shaw said Friday in an interview on Cheddar.
Eli Lilly ($LLY) just received clearance from the FDA for its latest drug, and it could change the lives of the 39 million Americans suffering from migraines, according to Shaw.
The treatment, Emgality, is a monthly, self-administered injection that will help patients cut the frequency of their migraines in half, she said.
Shaw said that many Americans conflate headaches and migraines, and so they often dismiss their pain. They key difference is that the symptoms of a migraine disrupt one's ability to function optimally through the day. That doesn't happen with a more commonplace headache. And a stigma contributes to the glaring statistic that only about 10 percent of those suffering from migraines take prescription drugs for prevention, Shaw said.
Emgality comes with a serious price tag: $6,900 a year, or $575 a month. But Eli Lilly is offering commercially insured patients up to 12 months of the drug for free. It's among the latest efforts from the industry to offer consumers some relief from surging drug costs.
Competitors Amgen ($AMGN) and Teva ($TEVA) have already unveiled new migraine treatment drugs.
For full interview [click here](https://cheddar.com/videos/eli-lilly-gets-fda-approval-for-new-migraine-treatment).
Carlo and Baker wrap up another week discussing the latest explosion in new Covid cases in the Northeast, President Biden's stalled agenda and more. Plus, Love, Hate, Ate featuring the question: why did movie dialogue get so hard to understand?
From extreme cold in Texas to devastating wildfires in California to the recent tornadoes in the Midwest, the U.S. experienced a string of severe weather events in 2021. Cheddar News speaks with climate expert Sweta Chakraborty on how these disasters are linked to climate change.
The sports world has been at the forefront of dealing with the pandemic ever since the NBA temporarily halted operations in March 2020 and opted to play in their Florida bubble. As the omicron variant and current COVID surge forces game postponements and player quarantines, how leagues manage to continue operations through the outbreaks could be a sign of what is to come for the general public. Dr. Robby Sikka, chair of the COVID Sports Society Workgroup and a former VP with the Minnesota Timberwolves, joined Cheddar's "Closing Bell" to talk about the ways in which the NBA, NHL, and NFL are innovating amid the disruptions.
According to the CDC, Black women are three to four times more likely to die from pregnancy-related causes than white women. The grim statistic is one of the main reasons why two organizations came together to do something. The Bump and the National Medical Association are partnering to launch The Black Maternal Health hub. The online resource will help expecting mothers feel supported, informed, and empowered throughout pregnancy and the early days of parenting. Jennifer Lee at The Bump and Dr. Rachel Villanueva, a clinical assistant professor of OB/GYN and member of the National Medical Association join Cheddar News to talk about the initiative.
Michelle Egger and Leila Strickland, Co-Founders of Biomilq, join Cheddar Innovates to discuss how their women-led team is recreating the process of milk production outside the body to combine both nutrition and practicality for new moms.
On this episode of Cheddar Innovates: Nucleus CEO breaks down what the future of the genomics industry looks like; Biomilq Co-Founders explains how they are is recreating the process of milk production outside the body to combine both nutrition and practicality for new moms; A look at Curiosity Stream's 'Top Science Stories 2021.'
Kian Sadeghi, Founder and CEO of Nucleus, joins Cheddar Innovates to discuss how he's making genetic analysis more accessible, what our genetic code can teach us about ourselves, and what the future of the genomics industry looks like.
On this episode of Cheddar Innovates: Omorpho Co-Founder explains the innovation driving gravity sportswear; Cool Beans CEO breaks down the science behind 'good mood food;' A look at Curiosity Stream's 'Building The James Webb Telescope.'
